A phase II study of guadecitabine combined with irinotecan vs regorafenib or TAS ‐102 in irinotecan‐refractory metastatic colorectal cancer patients
Valerie Lee, Rose Parkinson, Marianna Zahurak, Leslie Cope, Andrea Cercek, Henk Verheul, Elske Gootjes, Heinz Josef Lenz, Syma Iqbal, Peter Jones, Stephen Baylin, Vandna Rami, Nita Ahuja, Anthony El Khoueiry, Nilofer S. Azad - Cancer Research
- Oncology
Abstract
DNA methyltransferase inhibitors (DNMTi) have demonstrated benefit in reversing resistance to systemic therapies for several cancer types. In a phase II trial of guadecitabine and irinotecan compared to regorafenib or TAS‐102 in pts with advanced mCRC refractory to irinotecan. Patients with mCRC refractory to irinotecan were randomized 2:1 to guadecitabine and irinotecan (Arm A) vs standard of care regorafenib or TAS‐102 (Arm B) on a 28‐day cycle. Between January 15, 2016 and October 24, 2018, 104 pts were randomized at four international sites, with 96 pts undergoing treatment, 62 in Arm A and 34 in Arm B. Median overall survival was 7.15 months for Arm A and 7.66 months for Arm B (HR 0.93, 95% CI: 0.58–1.47, P = .75). The Kaplan–Meier rates of progression free survival at 4 months were 32% in Arm A and 26% in Arm B. Common ≥Grade 3 treatment related adverse events in Arm A were neutropenia (42%), anemia (18%), diarrhea (11%), compared to Arm B pts with neutropenia (12%), anemia (12%). Guadecitabine and irinotecan had similar OS compared to standard of care TAS‐102 or regorafenib, with evidence of target modulation. Clinical trial information: NCT01896856.